Publications by authors named "Y Tokuchi"
Article Synopsis
- - The study focused on the impact of muscle atrophy and high subcutaneous adipose tissue (SAT) radiodensity on prognosis in patients with hepatocellular carcinoma (HCC).
- - In a retrospective analysis of 201 patients, it was found that those with muscle atrophy (33.3%) and high SAT radiodensity (12.9%) had significantly worse survival outcomes compared to those without these conditions.
- - The findings suggest that recognizing patients with both muscle atrophy and high SAT radiodensity is crucial for developing targeted interventions, like nutritional therapy and exercise, to improve their health outcomes.
Cancers (Basel)
June 2023
Article Synopsis
- Lenvatinib, a treatment for unresectable hepatocellular carcinoma (HCC), can lead to appetite loss, but the reasons and effects were previously unclear.
- The study examined how changes in the hormone FGF21 during treatment relate to appetite changes in 63 HCC patients, measuring FGF21 levels at different times after starting lenvatinib.
- Findings revealed that patients who experienced significant appetite loss had a notable increase in FGF21 levels after 4 weeks of treatment, suggesting that monitoring FGF21 could help predict which patients are at higher risk for appetite loss and better understand the treatment’s side effects.
Article Synopsis
- The study investigates the recent prevalence of hepatitis delta virus (HDV) infections among patients with hepatitis B virus (HBV) in Japan, as it has not been updated for over two decades.
- Researchers screened 1,264 HBV patients at Hokkaido University Hospital, concluding that 1.7% had detectable anti-HDV antibodies.
- The findings indicate that those with anti-HDV antibodies had a higher prevalence of liver cirrhosis and experienced faster progression of liver fibrosis, emphasizing the need for routine HDV testing in similar patients.
Article Synopsis
- Atezolizumab plus bevacizumab shows effectiveness in treating unresectable hepatocellular carcinoma (HCC), but about 20% of patients may experience progressive disease (PD) shortly after starting treatment, highlighting the need for early detection methods.
- In a study, patients' serum was analyzed to identify biomarkers related to early PD; results indicated a significant difference in the cytokine CXCL9 levels between patients who developed early PD and those who did not.
- Lower serum CXCL9 levels (<333 pg/mL) were found to be predictive of early PD, with patients with these lower levels experiencing shorter progression-free survival compared to those without early PD.
